Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia

Leukemia

Volumn 21, Issue 1, 2007, Pages 53-60

  Spaner, D E ^a,b,c   Masellis, A ^d,e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d 3M COMPANY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

852A; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CANCER VACCINE; CPG 7909; CPG OLIGONUCLEOTIDE; CYTOTOXIC AGENT; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GUANOSINE DERIVATIVE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOTOXIN; INTERLEUKIN 2; LOXORIBINE; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; RITUXIMAB; S 28690; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNINDEXED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL MEDIATED CYTOTOXICITY; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CPG ISLAND; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SENSITIVITY; FATIGUE; HUMAN; MICROENVIRONMENT; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VASCULARIZATION;

EID: 33845542139     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404456     Document Type: Review

References (79)

1. Montserrat E. CLL therapy: Progress at last. Blood 2005; 105: 2-3.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-915.
3. Spaner D. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J Leukoc Biol 2004; 76: 338-351.
4. Medzhitov R, Preston P, Janeway C. A human homologue of Drosophila Toll signals activation of adaptive immunity. Nature 1997; 388: 394-397.
5. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15: 5-11.
6. Faure E, Equils O, Sieling P, Thomas L, Zhang F, Kirschning C et al. LPS activates NFkB through TLR4 in endothelial cells. J Biol Chem 2000; 275: 11058-11063.
7. Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of TLRs on human platelets. Immunol Cell Biol 2005; 83: 196-198.
8. Colonna M. Alerting DCs to pathogens: The importance of TLR signaling of stromal cells. Proc Natl Acad Sci USA 2004; 101: 16083-16084.
9. Peng SL. Signaling in B cells via TLRs. Curr Opin Immunol 2005; 17: 230-236.
10. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T et al. TLR8-mediated reversal of regulatory T cell function. Science 2005; 309: 1380-1384.
11. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137.
12. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. Recognition of ssRNA via TLR 7 and 8. Science 2004; 303: 1526-1529.
13. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
14. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of TLR7. Proc Natl Acad Sci USA 2003; 100: 6646-6651.
15. Kawai T, Akira S. Pathogen recognition with TLRs. Curr Opin Immunol 2005; 17: 338-344.
16. Li VW, Li WW, Talcott KE, Zhai AW. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005; 4: 708-717.
17. Gitelson E, Hammond C, Mena J, Lorenzo M, Buckstein R, Berinstein N et al. CLL-reactive T cells during tumor progression and after oxidized autologous tumor cell vaccines. Clin Can Res 2003; 9: 1656-1665.
18. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M et al. Identification of TAAs in CLL by SEREX. Blood 2002; 100: 2123-2131.
19. Konig A, Menzel T, Lynen S, Wrazel L, Rosen A, Al Katib A et al. bFGF upregulates the expression of bcl-2 in CLL cell lines resulting in delaying apoptosis. Leukemia 1997; 11: 258-265.
20. Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R et al. Elevated intracellular level of bFGF correlates with CLL stage and is associated with resistance to fludarabine. Blood 1996; 87: 1056-1063.
21. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D et al. Prognostic value of enhanced bone marrow angiogenesis in early B-CLL. Blood 2002; 100: 3344-3351.
22. Fillatreau S, Manz RA. Tolls for B cells. Eur J Immunol 2006; 36: 798-801.
23. Bernasconi NL, Onai N, Lanzavecchia A. A role for TLRs in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101: 4500-4504.
24. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of Toll-like receptors on B lymphocytes. Cell Immunol 2005; 236: 140-145.
25. Mansson A, Adner M, Hockerfelt U, Cardell LO. A distinct TLR repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation. Immunology 2006; 118: 539-548.
26. Anders HJ, Banas B, Schlondorff D. Signaling danger: Toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15: 854-867.
27. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S et al. Human TLR10 is a functional receptor, expressed by B cells and pDCs, which activates gene transcription through MyD88. J Immunol 2005; 174: 2942-2950.
28. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F et al. Subsets of human DC precursors express different TLRs and respond to different microbial antigens. J Exp Med 2001; 194: 863-869.
29. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and LPS activate TLRs at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-1968.
30. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, Hallman M. Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 2003; 33: 597-605.
31. Longo P, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P et al. The Akt signaling pathway determines the proliferative capacity of CLL-B cells from patients with progressive and stable disease. Leukemia 2006; 20: October 5 [E-pub ahead of print].
32. Spaner DE, Shi Y, Mena J, Hammond C, Tomic J, He L et al. Immunomodulatory effects of TLR7 activation on CLL cells. Leukemia 2006; 20: 286-295.
33. Decker T, Peschel C. Effect of CpG-oligonucleotides in CLL cells. Leuk Lymphoma 2001; 42: 301-307.
34. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S et al. pDCs control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005; 174: 4043-4050.
35. Spaner D, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a CLL patient treated with the Toll receptor-7/8 agonist, Imiquimod. Leuk Lymphoma 2005; 46: 935-939.
36. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F et al. IRAK1 plays an essential role for TLR7- and TLR9-mediated IFN induction. J Exp Med 2005; 201: 915-923.
37. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in CLL cells. Blood 2000; 95: 999-1006.
38. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72: 83-92.
39. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81-88.
40. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005; 11: 1490-1499.
41. Tomic J, White D, Shi Y, Mena J, Hammond C, He L et al. Sensitization of IL-2 signaling by TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006; 176: 3830-3839.
42. Schoenemeyer A, Barnes B, Mancl M, Latz E, Goutagny N, Pitha P et al. IRF5 is a central mediator of TLR7-signaling. J Biol Chem 2005; 280: 17005-17012.
43. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. IRF5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003; 63: 6424-6431.
44. Spaner DE, Hammond C, Mena J, Shi Y. Effect of IL-2R betabinding cytokines on costimulatory properties of CLL cells. Br J Haematol 2004; 127: 531-542.
45. Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L et al. Effect of serum and antioxidants on PKC-activated CLL cell immunogenicity. J Immunother 2005; 28: 28-39.
46. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NFκB by CDKs associated with p300. Science 1997; 275: 523-527.
47. Caligaris-Cappio F. The microenvironment in CLL. Br J Haematol 2003; 123: 380-388.
48. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F et al. Rapamycin-induced G1 arrest in cycling CLL cells is associated with reduced expression of cyclins D3, E, A, and survivin. Blood 2003; 101: 278-285.
49. Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J et al. Cell cycle progression of CLL cells is controlled by cyclins D2, D3, CDK4 and the cdk inhibitor p27. Leukemia 2002; 16: 327-334.
50. Goodman MG, Spinosa JC, Saven A, Piro LD, Wormsley S. New perspectives on the approach to CLL. Leuk Lymphoma 1996; 22: 1-10.
51. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54.
52. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
53. Caligaris-Cappio F, Hamblin TJ. CLL: A bird of a different feather. J Clin Oncol 1999; 17: 399-408.
54. Spaner DE, Hammond C, Mena J, Foden C, Deabreu A. A phase I/II trial of oxidized autologous tumor vaccines during the 'watch and wait' phase of CLL. Cancer Immunol Immunother 2005; 54: 635-646.
55. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis in CLL. Blood 2004; 103: 1202-1210.
56. Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005; 77: 378-387.
57. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG et al. p53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19: 1030-1032.
58. Suliman H, Carraway M, Welty K, Whorton A, Piantadosi C. LPS stimulates mitochondrial biogenesis via NRF-1. J Biol Chem 2003; 278: 41510-41518.
59. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in CLL. Curr Treat Options Oncol 2003; 4: 211-218.
60. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T. Sensitization of CLL cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002; 99: 1320-1326.
61. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE et al. Addition of rituximab may prolong progression-free survival and overall survival in patients with previously untreated CLL. Blood 2005; 105: 49-53.
62. Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S et al. Novel TLR 9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006; 12: 577-583.
63. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM et al. Targeting TLR9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11: 361-369.
64. Goodman MG, Wormsley SB, Spinosa JC, Piro LD. Loxoribine induces CLL cells to traverse the cell cycle. Blood 1994; 84: 3457-3464.
65. Tosi P, Zinzani PL, Pellacani A, Ottaviani E, Magagnoli M, Tura S. Loxoribine affects fludarabine activity on CLL cells. Leuk Lymphoma 1997; 26: 343-348.
66. Pellacani A, Tosi P, Zinzani PL, Ottaviani E, Albertini P, Magagnoli M et al. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated CLL cells. Leuk Lymphoma 1999; 33: 147-153.
67. Wooldridge JE, Weiner GJ. CpG DNA and cancer immunotherapy: orchestrating the antitumor response. Curr Opin Oncol 2003; 15: 440-445.
68. Weiner GJ, Witzig TE, Link BK. The University of Iowa/Mayo Clinic Lymphoma SPORE. Clin Adv Hematol Oncol 2004; 2: 57-59.
69. Agarwala SS, Kirkwood JM, Bryant J. Phase 1, randomized trial of Loxoribine in advanced cancer. Cytokines Cell Mol Ther 2000; 6: 171-176.
70. Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174: 1259-1268.
71. Dudek A et al. Immune response activation by a TLR-7 agonist: Results of a phase 1 study. J Clin Oncol 2005; 23: 2515a.
72. Kreitman RJ. Recombinant toxins for cancer treatment. Curr Opin Mol Ther 2003; 5: 44-51.
73. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. TLR agonist combinations synergistically trigger a Th1-polarizing program in DCs. Nat Immunol 2005; 6: 769-776.
74. Wingender G, Garbi N, Schumak B, Jungerkes F, Endl E, von Bubnoff D et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006; 36: 12-20.
75. Mellor A, Baban B, Chandler P, Manlapat A, Kahler D, Munn D. CpG oligonucleotides induce splenic CD19+ DCs to acquire IDO-dependent T cell regulatory functions via IFN signaling. J Immunol 2005; 175: 5601-5605.
76. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66: 3859-3868.
77. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A MicroRNA signature associated with prognosis and progression in CLL. N Engl J Med 2005; 353: 1793-1801.
78. Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A et al. P2X7R expression in evolutive and indolent forms of CLL. Blood 2002; 99: 706-708.
79. Akira S, Takeda K. TLR signalling. Nat Rev Immunol 2004; 4: 499-511.